How Kewalramani was paid
$21.1M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Stock | Incentive | Other | Total |
|---|---|---|---|---|---|
| Reshma KewalramaniCEO and President | $1,600,000 | $15,002,270 | $4,118,640 | $423,351 | $21,144,261 |
| Charles F. Wagner, Jr.EVP & Chief Operating and Financial Officer | $974,808 | $5,250,817 | $1,965,000 | $51,184 | $8,241,809 |
| Carmen BozicEVP & Chief Medical Officer | $835,000 | $4,375,531 | $1,378,251 | $57,539 | $6,646,321 |
| Amit SachdevEVP & Chief Patient and External Affairs Officer | $700,000 | $4,900,522 | $1,155,420 | $21,301 | $6,777,243 |
| Nia TatsisEVP & Chief Regulatory and Quality Officer | $750,000 | $4,900,522 | $1,282,163 | $42,235 | $6,974,920 |
| Stuart A. ArbuckleFormer EVP & Chief Operating Officer | $521,486 | $9,341,927 | — | $132,934 | $9,996,347 |
What changed and why
- $12BTotal revenues reached $12 billion in 2025, representing a 9% increase compared to 2024.
- $21.1MCEO Reshma Kewalramani received total compensation of $21,144,261 in fiscal year 2025.
- 131%The company achieved a leading performance rating of 131% for the 2025 annual bonus program.
- 92%The advisory vote on executive compensation received approximately 92% support at the prior annual meeting.
- Target equity levels were increased for the CEO and executive vice presidents based on peer group analysis.
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.